Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Wall Street Journal - January 29, 2007
Nicholas Zamiska, nicholas.zamiska@wsj.com
The decision was criticized by the pharmaceutical industry, which said Bangkok is considering allowing copycat versions of more drugs in the near future. The government's move was notable partly because it included the heart medicine, expanding the realm of drugs over which such conflicts have typically occurred.
Thailand's Ministry of Health confirmed Monday that the government had approved the sale and production of cheap, generic versions of Plavix, the blood-thinning drug originally developed by Sanofi-Aventis SA, of Paris, and now co-marketed in several countries with Bristol-Myers Squibb Co., of New York, and the HIV treatment Kaletra, made by Abbott Laboratories, of the U.S. World Trade Organization rules allow a government to unilaterally declare an emergency and make or sell patented drugs without the permission of the drug companies.
"We do not view [the move] as legal or in the best interests of patients," said Melissa Brotz, a spokeswoman for Abbott.
The decision "is a matter of serious concern for Bristol-Myers Squibb and the research-based pharmaceutical industry," said Laura Hortas, a spokeswoman for Bristol-Myers Squibb, adding that only Sanofi-Aventis markets Plavix in Thailand. Sanofi-Aventis wasn't available to comment.
Teera Chakajnarodom, president of the Pharmaceutical Research and Manufacturers Association, an industry group in Bangkok that represents the large international drug companies, including these three, said he has heard there are more products for which the government may allow copycat versions. While he declined to be more specific, he said that there are cardiovascular and cancer drugs under consideration, as well as others, made by Swiss and British drug firms.
"After the company does 10 years of research, and then suddenly the Thai government would like to impose the compulsory license, taking away their property, their assets -- this is not a good practice," Dr. Teera said. "They claim that the drug is far too expensive for the Thai public to have access. But they never approached the companies before. Everything is negotiable."
In fact, a government's ability to suspend a company's drug patent can prove a powerful bargaining chip in reducing prices. In July 2005, for instance, Brazil reached an agreement with Abbott that lowered the price of Kaletra while preserving the company's patent on the drug.
Indian generics makers, which for years have benefited from that country's lax patent laws, stand to benefit from the Thai decision. Bangkok is considering making its purchases from Hetero Drugs Ltd. and Cipla Ltd., both of India, according to Thawat Suntrajarn, director general of the Ministry of Health's department of disease control.
The ministry said the move was necessary to ensure that sick people had access to affordable drugs. "They are waiting for these drugs. But the Thai government does not have enough money to purchase these drugs at the existing price," Dr. Thawat said. Thailand's government has already suspended a foreign company's drug patent, announcing late last year that it would allow domestic production and imports of Merck & Co.'s AIDS drug Efavirenz.
Dr. Thawat said the government's move will cut the price of the HIV drug Kaletra in half, reducing the monthly cost per patient to about 3,000 Thai baht ($89.55) or less. At current prices, the government can afford to provide medicine to only one-fifth of the 500,000 people living with the HIV virus in Thailand, Public Health Minister Mongkol Na Songkhla told the Associated Press, adding that the ministry was willing to talk to the companies about importing their drugs at cheaper prices.
Kannikar Kijtiwatchakul, a campaigner in Thailand for Doctors Without Borders, told the AP the government's move was "a brave decision, despite both anticipated pressure from industry and possible threats to withdraw investments. The authorities have engaged in dialogue with companies before, but the discounts have been marginal."
P.T. Jayawickramarajah, the World Health Organization's representative to Thailand, said that "any country can make a decision on what is required for their own population. I think this is left to the government to decide what is best for their people."
In September, Thailand's armed forces overthrew the government in a coup that ended 15 years of democratic rule.
070129
WJ070104
Copyright © 2007 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .